PRCT Earnings Prediction
The chart below shows how PRCT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PRCT sees a +1.13% change in stock price 10 days leading up to the earnings, and a +2.75% change 10 days following the report. On the earnings day itself, the stock moves by +2.08%. This data can give you a slight idea of what to expect for the next quarter's release.
PRCT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
58.37M
66.29%
9.40%
Gross Margin
63.24%
17.61%
7.17%
Operating Margin
-38.42%
-47.34%
-23.59%
Net Margin
-35.93%
-48.77%
-25.19%
EPS
-0.40
-21.57%
-20.00%
No Data Available
PRCT Earnings Analysis
PROCEPT BioRobotics Corporation Common Stock Corporation (PRCT.O) Earnings Conference Call
Positive
Third Quarter Revenue Growth: Total revenue for the third quarter of 2024 was $58.4 million, representing growth of 66%, compared to the third quarter of 2023.
Quarterly Revenue Growth: U.S. revenue for the quarter was $52.2 million, representing growth of 62%, compared to the prior year period.
Installed Base Growth: We exited the third quarter of 2024 with a U.S. installed base of 445 systems, representing growth of 64%, compared to the prior year period.
International Revenue Growth: We generated $6.2 million of international revenue in the third quarter of 2024, representing growth of approximately 86%, compared to the prior year period.
Record Gross Margin Achievement: Gross margin for the third quarter of 2024 was 63.2%, representing an all-time high.
Negative
Operating Expenses Increase: Total operating expenses in the third quarter of 2024 were $59.3 million, compared to $44.5 million in the same period of the prior year, indicating a significant increase in costs.
Quarterly Net Loss Comparison: Net loss was $21 million for the third quarter of 2024, compared to $24.6 million in the same period of the prior year, reflecting ongoing financial challenges.
Adjusted EBITDA Loss Comparison: Adjusted EBITDA was a loss of $12.4 million, compared to a loss of $19.4 million in the third quarter of 2023, showing persistent operational difficulties.
Cash Flow Drain: Cash usage in the quarter was reported at $17.3 million, indicating a continued drain on financial resources.
Operating Expenses Growth Concerns: Operating expenses are expected to be approximately $231.5 million for the full year 2024, representing a growth of 29%, which raises concerns about cost management.
PRCT FAQs
How does PRCT typically perform around its earnings report dates?
Is PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PRCT Earning Call Sentiment
PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PRCT.O
-4.8%Positive
The earnings call highlights strong financial performance with record revenue growth and high gross margins, indicating strong demand and operational efficiency. Despite increased operating expenses, the company demonstrates a path to profitability with reduced net loss and improved EBITDA. The Q&A reveals positive analyst sentiment, particularly around product features and customer reception. However, lack of specific guidance on profitability and rep training is a concern. Given the company's market cap, the positive financial metrics and optimistic guidance suggest a likely stock price increase of 2% to 8% over the next two weeks.
